Exelixis | EXEL - Marktkapitalisierung





Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 3.57B 221M 2026-05
Agios Pharmaceuticals USD 2.01B 423M 2026-03
Akebia Therapeutics USD 427M 297M 2025-12
Amgen USD 189.89B 13.64B 2026-03
AstraZeneca USD 301.25B 13.1B 2026-03
Bayer EUR 37.69B 1.01B 2026-05
BioMarin Pharmaceutical USD 10.18B 683M 2026-05
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Cytokinetics USD 9.16B 975M 2026-05
Eisai JPY 1.25T 171.13B 2026-05
Eli Lilly USD 869.02B 146.97B 2026-03
Esperion Therapeutics USD 885M 351M 2025-12
Exelixis USD 14.34B 3.44B 2026-05
Genmab DKK 20.48B 1.02B 2025-12
Incyte USD 21.73B 3B 2026-05
Ionis Pharmaceuticals USD 12.46B 356M 2026-03
MacroGenics USD 102M 4M 2025-12
Merck USD 297.1B 35.84B 2026-03
Moderna USD 20.15B 8.53B 2026-03
Nektar Therapeutics USD 15.62B 14.76B 2026-05
Neurocrine Biosciences USD 15.15B 1.9B 2026-05
Novartis USD 232.75B 75B 2026-05
Pfizer USD 147.4B 6.42B 2026-05
Takeda JPY 8.33T 681.01B 2026-05
Ultragenyx Pharmaceutical USD 2.06B 1000K 2026-05
Xencor USD 795M 98M 2026-05